Clinical Study for Dimethyl Fumarate in Preserving Islet β-Cell Function in Type 1 Diabetes Mellitus

Recruiting now · Phase 3 · Has a placebo group

Conditions studied: Type 1 Diabetes

In brief

Purpose of the Clinical Trial: This clinical trial aims to investigate whether dimethyl fumarate can treat adults with newly diagnosed type 1 diabetes and to evaluate the safety profile of dimethyl fumarate. Primary Research Questions: Does dimethyl fumarate protect pancreatic beta-cell function in adults with newly diagnosed type 1 diabetes? What medical issues may arise in individuals taking dimethyl fumarate? Study Design: Researchers will compare dimethyl fumarate with a placebo (an identical substance without active ingredients) to determine whether Dimethyl fumarate can effectively treat type 1 diabetes. Participant Activities: Take dimethyl fumarate or placebo orally twice daily for 24 weeks. Attend on-site visits every 4 weeks during the intervention period and every 12 weeks after the intervention for examinations and assessments. Record symptoms, blood glucose control, islet function, and insulin usage throughout the trial.

Key facts

Study ID

NCT07258394

Run by

Nanjing Medical University

People needed

90

Starts

2026-01-27

Expected to finish

2028-12-31

Last updated by the study team

2026-03-05

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects who provide written informed consent.
• Aged 18-65 years.
• Diagnosed with Type 1 Diabetes Mellitus (per ADA 2024 criteria).
• Positive for ≥2 autoantibodies: Insulin autoantibody (IAA) Glutamic acid decarboxylase autoantibody (GADA) Protein tyrosine phosphatase antibody (IA-2A) Islet cell antibody (ICA) Zinc transporter 8 autoantibody (ZnT8A) Note: For IAA-positive subjects with insulin use >14 days, ≥2 additional autoantibodies must be positive.
• Disease duration ≤100 days post-T1DM diagnosis.
• Random C-peptide ≥ 200 pmol/L.

You may not qualify if…

• Pregnancy, lactation, or women of childbearing potential not using contraception.
• Well-controlled glycemia with oral hypoglycemic agents alone.
• Participation in other diabetes/immune-modulating trials.
• ALT/AST >3× upper limit of normal (ULN).
• History of malignancy, uncontrolled autoimmune disorders, or active infections.
• Alcohol/drug abuse, psychiatric disorders, or conditions unsuitable for trial participation.
• Use of immunosuppressants within 12 weeks prior.
• Participation in other drug trials within 12 weeks prior.
• History of drug allergies, hypersensitivity, or drug addiction.
• Any condition deemed by investigators to compromise study integrity.

Where it is running

• Deparement of Endocrinology and Metabolism, The First Affiliated Hospital with Nanjing Medical University — Nanjing, Jiangsu, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.